SCM
NDRM

Scopia Capital Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Scopia Capital Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-205,358
Closed -$7.99M – 37
2017
Q3 		$7.99M Sell
205,358
-4,178,000
-95% -$154M 0.13% 28
2017
Q2 		$131M Hold
4,383,358
– – 2.7% 14
2017
Q1 		$116M Hold
4,383,358
– – 2.15% 19
2016
Q4 		$97.3M Buy
4,383,358
+1,000,000
+30% +$18.7M 1.84% 19
2016
Q3 		$62.6M Hold
3,383,358
– – 1.1% 25
2016
Q2 		$55M Sell
3,383,358
-1
-0% -$17 1.14% 25
2016
Q1 		$47.8M Buy
3,383,359
+634,321
+23% +$8.57M 0.89% 26
2015
Q4 		$46.9M Buy
2,749,038
+1,405,497
+105% +$27.4M 0.93% 26
2015
Q3 		$27.8M Buy
+1,343,541
New +$27.6M 0.6% 28

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Scopia Capital Management's NDRM Position: Q4 2017 in Review

Scopia Capital Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 205,358 shares — an estimated $7.99M sold.

Scopia Capital Management first reported a position in NDRM in Q3 2015 and held it in 9 quarters. The position peaked at $131M in Q2 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Scopia Capital Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Scopia Capital Management sold 205,358 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $7.99M.
  • Scopia Capital Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2015 and held it in 9 quarters.
  • Scopia Capital Management's NeuroDerm Ltd. Ordinary Shares position peaked at $131M in Q2 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Scopia Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.